Starpharma Holdings Ltd. (OTCMKTS:SPHRY) Sees Large Decline in Short Interest

Starpharma Holdings Ltd. (OTCMKTS:SPHRY) was the target of a significant drop in short interest in the month of August. As of August 31st, there was short interest totaling 1 shares, a drop of 99.0% from the August 15th total of 101 shares. Based on an average trading volume of 769 shares, the days-to-cover ratio is presently 0.0 days. Currently, 0.0% of the shares of the company are sold short.

Starpharma Price Performance

OTCMKTS SPHRY opened at $5.35 on Friday. Starpharma has a 12-month low of $0.74 and a 12-month high of $5.82. The firm has a 50-day moving average price of $5.00 and a two-hundred day moving average price of $4.51.

Starpharma Company Profile

Starpharma is a clinical-stage biopharmaceutical company specializing in the development of dendrimer-based products across infectious disease, oncology and ophthalmology. Its proprietary dendrimer platform, DEP™ (Dendrimer Enhanced Products), enables precise molecular engineering to enhance drug delivery, targeting and safety profiles. The company’s lead product, VivaGel®, is a topical microbicide that has been approved in multiple markets for the treatment and prevention of bacterial vaginosis and is in clinical development for antiviral applications.

In addition to VivaGel, Starpharma is advancing pipeline candidates that leverage DEP technology to improve the performance of established and novel therapeutic agents.